PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Latest Information Update: 26 May 2026
At a glance
- Drugs Actinium 225 vipivotidum tetraxetan (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PSMAcTION
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 20 Feb 2026 Planned number of patients changed from 432 to 443.
- 03 Nov 2025 Planned End Date changed from 11 Apr 2033 to 19 Jul 2033.
- 03 Nov 2025 Planned primary completion date changed from 20 Mar 2028 to 27 Jun 2028.